The Effect of Rivaroxaban on Tunneled Cuffed Catheter Function in Hemodialysis Patients

The Effect of Rivaroxaban on Tunneled Cuffed Catheter Function in Hemodialysis Patients | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article The Effect of Rivaroxaban on Tunneled Cuffed Catheter Function in Hemodialysis Patients Min Li, Chen Chen, Chao Zhang, XiQuan Ni This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-9007315/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Objective To investigate the effect of oral rivaroxaban on tunneled cuffed catheter function in maintenance hemodialysis patients. Methods A single-center retrospective cohort study design was adopted. Clinical data were collected from 40 patients who underwent maintenance hemodialysis using tunneled cuffed catheters as vascular access in our hospital from February to October 2025. The patients were divided into two groups based on whether they received oral rivaroxaban during dialysis: 20 patients in the observation group (oral rivaroxaban 10 mg/day) and 20 patients in the control group (no anticoagulant or antiplatelet medications). The incidence of catheter dysfunction, dialysis adequacy indicators, coagulation function, and bleeding events were retrospectively analyzed and compared between the two groups. Results The incidence of catheter dysfunction in the observation group was significantly lower than that in the control group(p < 0.01). The Kt/V values in the observation group were higher than those in the control group at all follow-up time points and remained stable(p < 0.05; p < 0.01). The mean blood flow in the observation group was significantly higher than that in the control group at all post-treatment time points(p < 0.05; p 0.05). In the observation group, one patient experienced minor gingival bleeding, which resolved spontaneously without discontinuation of medication, while no bleeding events were observed in the control group. No severe bleeding or thromboembolic events occurred in either group. Conclusion Oral rivaroxaban (10 mg/day) effectively reduces the incidence of TCC dysfunction in MHD patients, contributes to maintaining dialysis adequacy, and shows a favorable safety profile without significant coagulation abnormalities or severe bleeding risk. Rivaroxaban Hemodialysis Tunneled cuffed catheter Catheter dysfunction Full Text Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-9007315","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":614134252,"identity":"2e06a98d-6f61-409d-ac63-d1dd249ff900","order_by":0,"name":"Min Li","email":"","orcid":"","institution":"China Rongtong Medical \u0026 Healthcare Group Tai'an 88 Hospital","correspondingAuthor":false,"prefix":"","firstName":"Min","middleName":"","lastName":"Li","suffix":""},{"id":614134253,"identity":"df5df13e-3739-4462-8c6d-35fb9fab4198","order_by":1,"name":"Chen Chen","email":"","orcid":"","institution":"China Rongtong Medical \u0026 Healthcare Group Tai'an 88 Hospital","correspondingAuthor":false,"prefix":"","firstName":"Chen","middleName":"","lastName":"Chen","suffix":""},{"id":614134254,"identity":"ed0114ce-62c2-4bd0-b408-5fa03d45631a","order_by":2,"name":"Chao Zhang","email":"","orcid":"","institution":"China Rongtong Medical \u0026 Healthcare Group Tai'an 88 Hospital","correspondingAuthor":false,"prefix":"","firstName":"Chao","middleName":"","lastName":"Zhang","suffix":""},{"id":614134255,"identity":"3a3d72b0-8e40-42fe-83c6-ff8a2a249505","order_by":3,"name":"XiQuan Ni","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAzklEQVRIiWNgGAWjYBACfvb+hw8+/rORs29vIFKLZM8ZZsMZbGnGBjwHiNRicCOHTZiH7XDiBokEYl125uwxxhk8hxO3Sz7eeIOhxiaaoA7G9r60Bx8k0o13zk4rtmA4lpbbQEgLM88Bc8MZBtayDbdzzCQYGw4T1sImkWAmzZPAzNhw8wyRWngkcoBaDjgrbrjBQ6QWCZ5jyYYzG9KMJXuAfkkgxi/2x5sPPvjYYCPHz354440PNTaEtSADA+KjBqGFVB2jYBSMglEwMgAAWFxDi84yTmIAAAAASUVORK5CYII=","orcid":"","institution":"China Rongtong Medical \u0026 Healthcare Group Tai'an 88 Hospital","correspondingAuthor":true,"prefix":"","firstName":"XiQuan","middleName":"","lastName":"Ni","suffix":""}],"badges":[],"createdAt":"2026-03-02 08:08:34","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-9007315/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-9007315/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":107890656,"identity":"53b17dc6-5cee-422f-a73d-89fbb1999822","added_by":"auto","created_at":"2026-04-27 09:56:36","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":264270,"visible":true,"origin":"","legend":"","description":"","filename":"Manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-9007315/v1_covered_648e0c6f-07ce-4ce0-b1bc-4530dae36523.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"The Effect of Rivaroxaban on Tunneled Cuffed Catheter Function in Hemodialysis Patients","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Rivaroxaban, Hemodialysis, Tunneled cuffed catheter, Catheter dysfunction","lastPublishedDoi":"10.21203/rs.3.rs-9007315/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-9007315/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eObjective\u003c/h2\u003e \u003cp\u003eTo investigate the effect of oral rivaroxaban on tunneled cuffed catheter function in maintenance hemodialysis patients.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eA single-center retrospective cohort study design was adopted. Clinical data were collected from 40 patients who underwent maintenance hemodialysis using tunneled cuffed catheters as vascular access in our hospital from February to October 2025. The patients were divided into two groups based on whether they received oral rivaroxaban during dialysis: 20 patients in the observation group (oral rivaroxaban 10 mg/day) and 20 patients in the control group (no anticoagulant or antiplatelet medications). The incidence of catheter dysfunction, dialysis adequacy indicators, coagulation function, and bleeding events were retrospectively analyzed and compared between the two groups.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eThe incidence of catheter dysfunction in the observation group was significantly lower than that in the control group(p\u0026thinsp;\u0026lt;\u0026thinsp;0.01). The Kt/V values in the observation group were higher than those in the control group at all follow-up time points and remained stable(p\u0026thinsp;\u0026lt;\u0026thinsp;0.05; p\u0026thinsp;\u0026lt;\u0026thinsp;0.01). The mean blood flow in the observation group was significantly higher than that in the control group at all post-treatment time points(p\u0026thinsp;\u0026lt;\u0026thinsp;0.05; p\u0026thinsp;\u0026lt;\u0026thinsp;0.01). No significant differences were observed in coagulation function indicators (PT, APTT, Fib) before and after treatment or between the two groups (all p\u0026thinsp;\u0026gt;\u0026thinsp;0.05). In the observation group, one patient experienced minor gingival bleeding, which resolved spontaneously without discontinuation of medication, while no bleeding events were observed in the control group. No severe bleeding or thromboembolic events occurred in either group.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eOral rivaroxaban (10 mg/day) effectively reduces the incidence of TCC dysfunction in MHD patients, contributes to maintaining dialysis adequacy, and shows a favorable safety profile without significant coagulation abnormalities or severe bleeding risk.\u003c/p\u003e","manuscriptTitle":"The Effect of Rivaroxaban on Tunneled Cuffed Catheter Function in Hemodialysis Patients","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-03-31 18:28:51","doi":"10.21203/rs.3.rs-9007315/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"ccff4103-f03e-4f2e-b8b5-e97c906550e2","owner":[],"postedDate":"March 31st, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2026-04-27T09:56:28+00:00","versionOfRecord":[],"versionCreatedAt":"2026-03-31 18:28:51","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-9007315","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-9007315","identity":"rs-9007315","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}